Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 290

1.

Extensive Emperipolesis of Neoplastic Lymphocytes by Mesothelial Cells in Pleural Effusion Cytology in a Case of a Mediastinal T-Cell Lymphoblastic Lymphoma: A Rare but Diagnostically Useful Phenomenon.

Haefliger S, Rebetez J, Buser PJ, Dirnhofer S, Bubendorf L.

Acta Cytol. 2019 Sep 17:1-5. doi: 10.1159/000502711. [Epub ahead of print]

PMID:
31527381
2.

JAK2 mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms.

Nageswara Rao T, Hansen N, Hilfiker J, Rai S, Majewska JM, Leković D, Gezer D, Andina N, Galli S, Cassel T, Geier F, Delezie J, Nienhold R, Hao-Shen H, Beisel C, Di Palma S, Dimeloe S, Trebicka J, Wolf D, Gassmann M, Fan TW, Lane AN, Handschin C, Dirnhofer S, Kröger N, Hess C, Radimerski T, Koschmieder S, Čokić VP, Skoda RC.

Blood. 2019 Sep 11. pii: blood.2019000162. doi: 10.1182/blood.2019000162. [Epub ahead of print]

PMID:
31511238
3.

How to resolve a clinical and molecular puzzle: concomitant monoclonal gammopathy of undetermined significance (MGUS) with neutrophilia and clonal hematopoiesis of indeterminate potential (CHIP).

Haefliger S, Juskevicius D, Höller S, Buser U, Dirnhofer S, Tzankov A.

Ann Hematol. 2019 Oct;98(10):2431-2432. doi: 10.1007/s00277-019-03786-9. Epub 2019 Aug 20. No abstract available.

PMID:
31432215
4.

Publisher Correction: Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion.

Paczulla AM, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Wang H, Tandler C, Mbarga M, Schaefer T, Falcone M, Nievergall E, Dörfel D, Hanns P, Passweg JR, Lutz C, Schwaller J, Zeiser R, Blazar BR, Caligiuri MA, Dirnhofer S, Lundberg P, Kanz L, Quintanilla-Martinez L, Steinle A, Trumpp A, Salih HR, Lengerke C.

Nature. 2019 Aug;572(7770):E19. doi: 10.1038/s41586-019-1475-x.

PMID:
31367045
5.

Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.

Spriano F, Tarantelli C, Gaudio E, Gerlach MM, Priebe V, Cascione L, Bernasconi E, Targa A, Mascia M, Dirnhofer S, Stathis A, Zucca E, Bertoni F.

Br J Haematol. 2019 Jul 29. doi: 10.1111/bjh.16118. [Epub ahead of print]

PMID:
31355927
6.

Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion.

Paczulla AM, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Wang H, Tandler C, Mbarga M, Schaefer T, Falcone M, Nievergall E, Dörfel D, Hanns P, Passweg JR, Lutz C, Schwaller J, Zeiser R, Blazar BR, Caligiuri MA, Dirnhofer S, Lundberg P, Kanz L, Quintanilla-Martinez L, Steinle A, Trumpp A, Salih HR, Lengerke C.

Nature. 2019 Aug;572(7768):254-259. doi: 10.1038/s41586-019-1410-1. Epub 2019 Jul 17. Erratum in: Nature. 2019 Aug 1;:.

PMID:
31316209
7.

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.

Zucca E, Rondeau S, Vanazzi A, Østenstad B, Mey UJM, Rauch D, Wahlin BE, Hitz F, Hernberg M, Johansson AS, de Nully Brown P, Hagberg H, Ferreri AJM, Lohri A, Novak U, Zander T, Bersvendsen H, Bargetzi M, Mingrone W, Krasniqi F, Dirnhofer S, Hayoz S, Hawle H, Vilei SB, Ghielmini M, Kimby E; Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group.

Blood. 2019 Jul 25;134(4):353-362. doi: 10.1182/blood-2018-10-879643. Epub 2019 May 17.

PMID:
31101627
8.

Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses.

Cascione L, Rinaldi A, Bruscaggin A, Tarantelli C, Arribas AJ, Kwee I, Pecciarini L, Mensah AA, Spina V, Chung EYL, Terzi di Bergamo L, Dirnhofer S, Tzankov A, Miranda RN, Young KH, Traverse-Glehen A, Gaidano G, Swerdlow SH, Gascoyne R, Rabadan R, Ponzoni M, Bhagat G, Rossi D, Zucca E, Bertoni F.

Haematologica. 2019 Apr 24. pii: haematol.2018.214957. doi: 10.3324/haematol.2018.214957. [Epub ahead of print]

9.

Transformation of a splenic marginal zone lymphoma into classic Hodgkin lymphoma.

Menter T, Dirnhofer S, Tzankov A.

J Clin Pathol. 2019 May;72(5):391-392. doi: 10.1136/jclinpath-2018-205678. Epub 2019 Feb 27. No abstract available.

PMID:
30814198
10.

Cancer immunology, inflammation, and tolerance: an introduction.

Dirnhofer S, Zippelius A.

Virchows Arch. 2019 Apr;474(4):405-406. doi: 10.1007/s00428-019-02547-3. No abstract available.

PMID:
30796517
11.

Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.

Stivala S, Codilupi T, Brkic S, Baerenwaldt A, Ghosh N, Hao-Shen H, Dirnhofer S, Dettmer MS, Simillion C, Kaufmann BA, Chiu S, Keller M, Kleppe M, Hilpert M, Buser AS, Passweg JR, Radimerski T, Skoda RC, Levine RL, Meyer SC.

J Clin Invest. 2019 Mar 4;130:1596-1611. doi: 10.1172/JCI98785. eCollection 2019 Mar 4.

12.

ALK-negative anaplastic large cell lymphoma arising in the thrombus of an aortic prosthesis preceeded by clonally related lymphomatoid papulosis.

Menter T, Ballova V, Caspar C, Wolff T, Kasenda B, Singer G, Juskevicius D, Tzankov A, Dirnhofer S.

Virchows Arch. 2019 Jun;474(6):763-767. doi: 10.1007/s00428-019-02531-x. Epub 2019 Jan 26.

PMID:
30685783
13.

RUNX1 Mutations Can Lead to Aberrant Expression of CD79a and PAX5 in Acute Myelogenous Leukemias: A Potential Diagnostic Pitfall.

Menter T, Lundberg P, Wenzel F, Dirks J, Fernandez P, Friess D, Dirnhofer S, Tzankov A.

Pathobiology. 2019;86(2-3):162-166. doi: 10.1159/000493688. Epub 2018 Nov 5.

PMID:
30396184
14.

TIRAP p.R81C is a novel lymphoma risk variant which enhances cell proliferation via NF-κB mediated signaling in B-cells.

Burkhard R, Keller I, Arambasic M, Juskevicius D, Tzankov A, Lundberg P, Bruggmann R, Dirnhofer S, Radpour R, Novak U.

Haematologica. 2019 Apr;104(4):766-777. doi: 10.3324/haematol.2018.201590. Epub 2018 Oct 31.

15.

T-lymphoblastic lymphoma after previous thymoma: how NGS helps establishing the diagnosis and procures new insights.

Le Clef Q, Ortega-Sanchez G, Dirnhofer S, Tzankov A.

Leuk Lymphoma. 2019 May;60(5):1320-1323. doi: 10.1080/10428194.2018.1520993. Epub 2018 Oct 10. No abstract available.

PMID:
30301393
16.

Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy.

Läubli H, Dirnhofer S, Zippelius A.

Virchows Arch. 2019 Apr;474(4):485-495. doi: 10.1007/s00428-018-2435-9. Epub 2018 Aug 25.

PMID:
30143868
17.

Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals.

Conconi A, Zucca E, Margiotta-Casaluci G, Darling K, Hasse B, Battegay M, Staehelin C, Novak U, Schmid P, Scherrer A, Dirnhofer S, Kwee I, Nassi L, Cavalli F, Gaidano G, Bertoni F, Bernasconi E; Swiss HIV Cohort study (SHCS).

Hematol Oncol. 2018 Dec;36(5):757-764. doi: 10.1002/hon.2536. Epub 2018 Aug 16.

PMID:
30113708
18.

Novel cell enrichment technique for robust genetic analysis of archival classical Hodgkin lymphoma tissues.

Juskevicius D, Jucker D, Dietsche T, Perrina V, Rufle A, Ruiz C, Dirnhofer S, Tzankov A.

Lab Invest. 2018 Nov;98(11):1487-1499. doi: 10.1038/s41374-018-0096-6. Epub 2018 Aug 7.

PMID:
30087457
19.

Localized pain-causing JAK2-V617F-positive myeloproliferation with normal peripheral blood values.

Gerlach MM, Arranto C, Dirnhofer S, Tzankov A.

Ann Hematol. 2018 Nov;97(11):2265-2266. doi: 10.1007/s00277-018-3363-0. Epub 2018 May 16. No abstract available.

PMID:
29766235
20.

High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations.

Pillonel V, Juskevicius D, Ng CKY, Bodmer A, Zettl A, Jucker D, Dirnhofer S, Tzankov A.

Leukemia. 2018 Nov;32(11):2412-2426. doi: 10.1038/s41375-018-0082-4. Epub 2018 Feb 28.

21.

Clonogenic versus morphogenic mutations in myeloid neoplasms: chronologic observations in a U2AF1, TET2, CSF3R and JAK2 'co-mutated' myeloproliferative neoplasm suggest a hierarchical order of mutations and potential predictive value for kinase inhibitor treatment response.

Gerlach MM, Lundberg P, Halter J, Arranto C, Wenzel F, Dirnhofer S, Tzankov A.

Leuk Lymphoma. 2018 Aug;59(8):1994-1997. doi: 10.1080/10428194.2017.1406087. Epub 2017 Dec 3. No abstract available.

PMID:
29199511
22.

ACKR3 expression on diffuse large B cell lymphoma is required for tumor spreading and tissue infiltration.

Puddinu V, Casella S, Radice E, Thelen S, Dirnhofer S, Bertoni F, Thelen M.

Oncotarget. 2017 Jun 29;8(49):85068-85084. doi: 10.18632/oncotarget.18844. eCollection 2017 Oct 17.

23.

mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition.

Xue G, Kohler R, Tang F, Hynx D, Wang Y, Orso F, Prêtre V, Ritschard R, Hirschmann P, Cron P, Roloff T, Dummer R, Mandalà M, Bichet S, Genoud C, Meyer AG, Muraro MG, Spagnoli GC, Taverna D, Rüegg C, Merghoub T, Massi D, Tang H, Levesque MP, Dirnhofer S, Zippelius A, Hemmings BA, Wicki A.

Oncotarget. 2017 May 25;8(41):69204-69218. doi: 10.18632/oncotarget.18213. eCollection 2017 Sep 19.

24.

Lymphomdiagnostik durch den Pathologen – von der Morphologie über den Immunphänotyp bis zur Genanalyse.

Menter T, Tzankov A, Dirnhofer S.

Ther Umsch. 2017 Sep;74(4):197-203. doi: 10.1024/0040-5930/a000904. Review. German. No abstract available.

PMID:
28950777
25.

The clinicopathologic spectrum of mature aggressive B cell lymphomas.

Rimsza L, Pittaluga S, Dirnhofer S, Copie-Bergman C, de Leval L, Facchetti F, Pileri S, Rosenwald A, Wotherspoon A, Fend F.

Virchows Arch. 2017 Oct;471(4):453-466. doi: 10.1007/s00428-017-2199-7. Epub 2017 Aug 26. Review.

PMID:
28844114
26.

Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases.

Facchetti F, Pileri SA, Lorenzi L, Tabanelli V, Rimsza L, Pittaluga S, Dirnhofer S, Copie-Bergman C, de Leval L, Rosenwald A, Wotherspoon A, Fend F.

Virchows Arch. 2017 Oct;471(4):467-489. doi: 10.1007/s00428-017-2176-1. Epub 2017 Jul 10.

PMID:
28695297
27.

Beneficial role of increased FOXP3+ regulatory T-cells in acute myeloid leukaemia therapy response.

Menter T, Kuzmanic B, Bucher C, Medinger M, Halter J, Dirnhofer S, Tzankov A.

Br J Haematol. 2018 Aug;182(4):581-583. doi: 10.1111/bjh.14819. Epub 2017 Jun 27. No abstract available.

PMID:
28653378
28.

A pattern-based approach to reactive lymphadenopathies.

Tzankov A, Dirnhofer S.

Semin Diagn Pathol. 2018 Jan;35(1):4-19. doi: 10.1053/j.semdp.2017.05.002. Epub 2017 May 25. Review.

PMID:
28619469
29.

B-cell lymphomas with discordance between pathological features and clinical behavior.

de Leval L, Copie-Bergman C, Rosenwald A, Rimsza L, Pittaluga S, Bisig B, Dirnhofer S, Facchetti F, Pileri S, Fend F, Wotherspoon A.

Virchows Arch. 2017 Oct;471(4):439-451. doi: 10.1007/s00428-017-2152-9. Epub 2017 Jun 1.

PMID:
28573510
30.

Genetic background and evolution of relapses in aggressive B-cell lymphomas.

Juskevicius D, Dirnhofer S, Tzankov A.

Haematologica. 2017 Jul;102(7):1139-1149. doi: 10.3324/haematol.2016.151647. Epub 2017 May 29. Review.

31.

Quality assurance trials for Ki67 assessment in pathology.

Raap M, Ließem S, Rüschoff J, Fisseler-Eckhoff A, Reiner A, Dirnhofer S, von Wasielewski R, Kreipe H.

Virchows Arch. 2017 Oct;471(4):501-508. doi: 10.1007/s00428-017-2142-y. Epub 2017 May 11.

PMID:
28497316
32.

Mutational landscape of B-cell post-transplant lymphoproliferative disorders.

Menter T, Juskevicius D, Alikian M, Steiger J, Dirnhofer S, Tzankov A, Naresh KN.

Br J Haematol. 2017 Jul;178(1):48-56. doi: 10.1111/bjh.14633. Epub 2017 Apr 17.

PMID:
28419429
33.

Diagnostic Utility of Lymphoid Enhancer Binding Factor 1 Immunohistochemistry in Small B-Cell Lymphomas.

Menter T, Trivedi P, Ahmad R, Flora R, Dirnhofer S, Tzankov A, Naresh KN.

Am J Clin Pathol. 2017 Mar 1;147(3):292-300. doi: 10.1093/ajcp/aqw208.

PMID:
28395058
34.

Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.

Juskevicius D, Jucker D, Klingbiel D, Mamot C, Dirnhofer S, Tzankov A.

J Hematol Oncol. 2017 Mar 17;10(1):70. doi: 10.1186/s13045-017-0438-7.

35.

Long-term observation reveals high-frequency engraftment of human acute myeloid leukemia in immunodeficient mice.

Paczulla AM, Dirnhofer S, Konantz M, Medinger M, Salih HR, Rothfelder K, Tsakiris DA, Passweg JR, Lundberg P, Lengerke C.

Haematologica. 2017 May;102(5):854-864. doi: 10.3324/haematol.2016.153528. Epub 2017 Feb 9.

36.

Sharing of a PTPN11 mutation by myelodysplastic bone marrow and a mature plasmacytoid dendritic cell proliferation provides evidence for their common myelomonocytic origin.

Bodmer A, Menter T, Juskevicius D, Arranto C, Wenzel F, Dirnhofer S, Tzankov A.

Virchows Arch. 2017 Apr;470(4):469-473. doi: 10.1007/s00428-017-2075-5. Epub 2017 Jan 23. No abstract available.

PMID:
28116520
37.

[Abdominal pain and hypertension in a 55-year-old male patient].

Kofler T, Yueksel F, Dirnhofer S, Donath MY, Trendelenburg M.

Internist (Berl). 2017 Apr;58(4):397-401. doi: 10.1007/s00108-016-0170-3. German.

PMID:
28005140
38.

Lymphadenectomy Specimens in a Large Retrospective Cohort of Pediatric Patients Reveal No in situ Lymphomas but a Broad Spectrum of Reactive Changes.

Banz Y, Tzankov A, Dirnhofer S, Perren A, Hoeller S.

Pathobiology. 2017;84(3):139-143. doi: 10.1159/000449253. Epub 2016 Nov 3.

39.

Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis.

Shimizu T, Kubovcakova L, Nienhold R, Zmajkovic J, Meyer SC, Hao-Shen H, Geier F, Dirnhofer S, Guglielmelli P, Vannucchi AM, Feenstra JD, Kralovics R, Orkin SH, Skoda RC.

J Exp Med. 2016 Jul 25;213(8):1479-96. doi: 10.1084/jem.20151136. Epub 2016 Jul 11.

40.

JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis.

Grisouard J, Li S, Kubovcakova L, Rao TN, Meyer SC, Lundberg P, Hao-Shen H, Romanet V, Murakami M, Radimerski T, Dirnhofer S, Skoda RC.

Blood. 2016 Aug 11;128(6):839-51. doi: 10.1182/blood-2015-12-689216. Epub 2016 Jun 10.

41.

Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis.

Juskevicius D, Lorber T, Gsponer J, Perrina V, Ruiz C, Stenner-Liewen F, Dirnhofer S, Tzankov A.

Leukemia. 2016 Dec;30(12):2385-2395. doi: 10.1038/leu.2016.135. Epub 2016 May 20.

PMID:
27198204
42.

Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas.

Menter T, Bodmer-Haecki A, Dirnhofer S, Tzankov A.

Hum Pathol. 2016 Aug;54:17-24. doi: 10.1016/j.humpath.2016.03.005. Epub 2016 Apr 1.

PMID:
27045512
43.

Comprehensive phenotypic characterization of PTLD reveals potential reliance on EBV or NF-κB signalling instead of B-cell receptor signalling.

Menter T, Dickenmann M, Juskevicius D, Steiger J, Dirnhofer S, Tzankov A.

Hematol Oncol. 2017 Jun;35(2):187-197. doi: 10.1002/hon.2280. Epub 2016 Jan 22.

PMID:
26799990
44.

The heterogeneity of follicular lymphomas: from early development to transformation.

Xerri L, Dirnhofer S, Quintanilla-Martinez L, Sander B, Chan JK, Campo E, Swerdlow SH, Ott G.

Virchows Arch. 2016 Feb;468(2):127-39. doi: 10.1007/s00428-015-1864-y. Epub 2015 Oct 19. Review.

PMID:
26481245
45.

The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing.

Swerdlow SH, Kuzu I, Dogan A, Dirnhofer S, Chan JK, Sander B, Ott G, Xerri L, Quintanilla-Martinez L, Campo E.

Virchows Arch. 2016 Mar;468(3):259-75. doi: 10.1007/s00428-015-1858-9. Epub 2015 Oct 10. Review.

46.

Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis - a consensus-based study.

Kvasnicka HM, Beham-Schmid C, Bob R, Dirnhofer S, Hussein K, Kreipe H, Kremer M, Schmitt-Graeff A, Schwarz S, Thiele J, Werner M, Stein H.

Histopathology. 2016 May;68(6):905-15. doi: 10.1111/his.12871. Epub 2015 Nov 20.

PMID:
26402166
47.

[Tumors of dendritic and other accessory cells of lymph nodes].

Tzankov A, Dirnhofer S.

Pathologe. 2015 Sep;36(5):467-76. doi: 10.1007/s00292-015-0042-y. Review. German.

PMID:
26305140
48.

Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).

Mamot C, Klingbiel D, Hitz F, Renner C, Pabst T, Driessen C, Mey U, Pless M, Bargetzi M, Krasniqi F, Gigli F, Hany T, Samarin A, Biaggi C, Rusterholz C, Dirnhofer S, Zucca E, Martinelli G.

J Clin Oncol. 2015 Aug 10;33(23):2523-9. doi: 10.1200/JCO.2014.58.9846. Epub 2015 Jul 6. Erratum in: J Clin Oncol. 2015 Sep 20;33(27):3074.

PMID:
26150440
49.

Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.

Tzankov A, Leu N, Muenst S, Juskevicius D, Klingbiel D, Mamot C, Dirnhofer S.

J Hematol Oncol. 2015 Jun 14;8:70. doi: 10.1186/s13045-015-0168-7.

50.

LEF1: a highly specific marker for the diagnosis of chronic lymphocytic B cell leukaemia/small lymphocytic B cell lymphoma.

Menter T, Dirnhofer S, Tzankov A.

J Clin Pathol. 2015 Jun;68(6):473-8. doi: 10.1136/jclinpath-2015-202862. Epub 2015 Feb 24.

PMID:
25713417

Supplemental Content

Loading ...
Support Center